Observational studyInternational ophthalmology2026
FilmArray® multiplex PCR panels on corneal swabs in suspected infectious keratitis: a pragmatic real-world study.
Observational study in International ophthalmology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo evaluate the clinical utility of a pragmatic, off-label multiplex PCR strategy using FilmArray® panels on corneal swabs in suspected infectious keratitis, with emphasis on diagnostic yield, turnaround time, and early therapeutic impact in routine care.
methodsThis prospective, single-center observational study was conducted over 24 months (January 2024-December 2025) at a tertiary referral center. In episodes of clinically suspected infectious keratitis, corneal swabs were immersed in brain-heart infusion medium. A FilmArray® Meningitis/Encephalitis (ME) panel was used as first-line testing, with selective FilmArray® Blood Culture Identification 2 (BCID2) panel use when clinically indicated. Conventional bacterial and fungal cultures were systematically performed. Outcomes included diagnostic yield of the PCR algorithm, turnaround time (TAT), concordance patterns with culture, and early treatment changes after PCR results.
resultsFifty episodes were included. The multiplex PCR algorithm (ME ± BCID2) detected at least one pathogen in 50% of cases, with viral detections, mainly herpes simplex virus type 1, accounting for a substantial proportion of PCR-positive results. Conventional culture was positive in 32% of cases and identified bacterial and/or fungal pathogens. Median TAT was 6.5 h for PCR versus 79 h for culture, corresponding to a median reduction of 72.5 h. PCR findings were associated with treatment modification within 24 h in 32% of cases, with additional changes after 48 h in 6%, predominantly antiviral initiation or targeted antimicrobial adjustment.
conclusionsIn this real-world exploratory study, the main advantage of the pragmatic FilmArray® strategy was the marked reduction in turnaround time compared with culture, providing microbiological information within hours rather than days. Because PCR and culture differ fundamentally in detectable pathogen classes, particularly due to viral detection by PCR, these findings should not be interpreted as evidence of diagnostic superiority. FilmArray® testing may serve as a complementary approach in selected severe, atypical, pretreated, or culture-negative keratitis cases when rapid therapeutic decisions are needed.
Indexed as
Identifiers
42133105What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.